Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium
- PMID: 2392160
- DOI: 10.1007/BF00171739
Antagonism of novel inotropic agents at A1 adenosine receptors and m-cholinoceptors in human myocardium
Abstract
The effects of the new inotropic agents saterinone, sulmazole, UD-CG 212.Cl and milrinone at A1 adenosine receptors and m-cholinoceptors were evaluated in human myocardium from patients with heart failure. At A1 adenosine receptors, all compounds inhibited 3H-DPCPX-binding to ventricular membrane preparations at micromolar concentrations. As judged from the K1-values, the rank order of potency was saterinone greater than sulmazole greater than UD-CG 212.Cl greater than milrinone. The new inotropic agents also displaced the binding of 3H-QNB at m-cholinoceptors. Except for saterinone, the concentration ranges of mean Ki-values were considerably higher at m-cholinoceptors than at A1 adenosine receptors. The rank order of potency was saterinone greater than sulmazole greater than UD-CG 212.Cl greater than milrinone. Competition of the A1 adenosine receptor agonist R-PIA to 3H-DPCPX-binding showed a biphasic curve with a shallow slope (Hill coefficient nH = 0.63) and revealed two affinity states of the A1 adenosine receptor. In the presence of guanine nucleotides [Gpp(NH)p], the competition curve showed one low affinity class of binding sites and was shifted to the right. In contrast, the competition curves of the new inotropic agents were characterized by a monophasic, steeper slope (mean Hill coefficient nH = 0.98). Guanine nucleotides had no effect. Similar results were obtained with saterinone and carbachol at m-cholinoceptors. Competition with carbachol revealed three affinity states of the m-cholinoceptor, the super-high affinity binding was reversed by Gpp(NH)p. Competition with saterinone revealed one class of binding sites which was not influenced by Gpp(NH)p.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Increase of Gi alpha in human hearts with dilated but not ischemic cardiomyopathy.Circulation. 1990 Oct;82(4):1249-65. doi: 10.1161/01.cir.82.4.1249. Circulation. 1990. PMID: 2169357
-
Characterization of A1 adenosine receptors in atrial and ventricular myocardium from diseased human hearts.Circ Res. 1989 Nov;65(5):1201-11. doi: 10.1161/01.res.65.5.1201. Circ Res. 1989. PMID: 2553291
-
Coupling of M-cholinoceptors and A1 adenosine receptors in human myocardium.Am J Physiol. 1994 May;266(5 Pt 2):H1951-8. doi: 10.1152/ajpheart.1994.266.5.H1951. Am J Physiol. 1994. PMID: 8203594
-
Comparison of effects of MgCl2 and Gpp(NH)p on antagonist and agonist radioligand binding to adenosine A1 receptors.Acta Pharmacol Sin. 2003 Aug;24(8):729-40. Acta Pharmacol Sin. 2003. PMID: 12904270
-
Species comparison of adenosine and beta-adrenoceptors in mammalian atrial and ventricular myocardium.Eur J Pharmacol. 1993 Jul 15;246(2):105-11. doi: 10.1016/0922-4106(93)90086-o. Eur J Pharmacol. 1993. PMID: 8397091
Cited by
-
Drugs to facilitate recovery of neuromuscular blockade and muscle strength.J Anesth. 2005;19(4):302-8. doi: 10.1007/s00540-005-0336-y. J Anesth. 2005. PMID: 16261467 Review.
-
EMD 53998 acts as Ca(2+)-sensitizer and phosphodiesterase III-inhibitor in human myocardium.Basic Res Cardiol. 1995 Sep-Oct;90(5):365-71. doi: 10.1007/BF00788497. Basic Res Cardiol. 1995. PMID: 8585857
-
Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.Drugs Aging. 1994 May;4(5):417-41. doi: 10.2165/00002512-199404050-00007. Drugs Aging. 1994. PMID: 8043944 Review.
References
MeSH terms
Substances
LinkOut - more resources
Research Materials